Australia markets open in 1 hour 23 minutes

Lumos Pharma, Inc. (LUMO)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
9.09+1.10 (+13.77%)
At close: 04:00PM EST
9.19 +0.22 (+2.45%)
After hours: 04:12PM EST
Full screen
Trade prices are not sourced from all markets
Previous close7.99
Open7.81
Bid8.90 x 1300
Ask9.20 x 1000
Day's range7.72 - 9.09
52-week range6.15 - 20.34
Volume113,722
Avg. volume38,954
Market cap75.969M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-3.27
Earnings date07 Mar 2022 - 11 Mar 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est25.00
  • GlobeNewswire

    Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

    AUSTIN, Texas, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will present at the H.C. Wainwright Virtual BIOCONNECT Conference being held January 10-13, 2022. A webcast of the presentation will be available at 7:00AM ET on January 10th through the following link: https://journey.ct.events/view/d2cd046c-ff2c-40ea-acdc-340df7150783 and on Lumos Pharma’s website in

  • Zacks

    Down 16.1% in 4 Weeks, Here's Why Lumos (LUMO) Looks Ripe for a Turnaround

    Lumos (LUMO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

  • Simply Wall St.

    We're Hopeful That Lumos Pharma (NASDAQ:LUMO) Will Use Its Cash Wisely

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...